Home > Insider Trading > Filing (0001209191-21-069493)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1490978	Schrodinger Inc.	SDGR	Pharmaceutical Preparations (2834)	954284541

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1798179	Lorne Robert Abel	C/O Schrodinger, Inc., 1540 Broadway, 24Th Floor New York NY 10036	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-12-13	15,601	$17.00	15,601	No	4	M	Direct
Common Stock	Disposition	2021-12-13	13,701	$36.20	1,900	No	4	S	Direct
Common Stock	Disposition	2021-12-13	1,900	$36.88	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-12-13	15,601	$0.00	15,601	$17.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
94,756		2030-02-05	No	4	M	Direct

Footnotes

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.77 to $36.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.78 to $36.99, inclusive.
This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024.